Mr. McCAIN. Mr. President, I fully support the passage of S. 3187, the Food and Drug Administration, FDA, Safety and Innovation Act. This important piece of legislation reauthorizes and establishes important user fee agreements for drugs, devices, generic drugs and biosimilar biological products. Furthermore, the bill improves the medical device approval process and modernizes FDA's global drug supply chain authority to ensure that the drug manufacturing process is safer.
The legislation also contains provisions to incentivize development of pediatric drugs and devices, spur innovation of new drug therapies for life-threatening medical conditions, mitigate drug shortages, and improve agency accountability and transparency in the drug and device approval process.
Unfortunately, Mr. President, I was necessarily absent from the Senate and, therefore, unable to cast my vote in support of this bill.